1-3 of 3
Lenushka Maharaj, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Sunil Iyengar, MD, Andrew J. Clear, BSc, Andrew Owen, Lenushka Maharaj, MSc, Janet Matthews, Maria Calaminici, MD, Rebecca Auer, MD, Essam Ghazaly, MD, Sameena Iqbal, John G. Gribben, MD, DSc, Simon Joel, BSc(Hons), PhD
Journal: Blood
Blood (2011) 118 (21): 1654.
https://doi.org/10.1182/blood.V118.21.1654.1654
Published: 2011
Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD
Journal: Blood
Blood (2004) 104 (11): 1386.
https://doi.org/10.1182/blood.V104.11.1386.1386
Published: 2004
Journal Articles

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

Lenushka Maharaj, MSc, Sandra J. Strauss, MD, Jim Stec, Thomas A. Lister, Simon P. Joel, PhD
Journal: Blood
Blood (2004) 104 (11): 3294.
https://doi.org/10.1182/blood.V104.11.3294.3294
Published: 2004